NeuroOne Medical Technologies Corporation (NMTC)

NMTC Balance Sheet

Financials in millions USD. Fiscal year is October - September.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	5.32	8.16	6.9	4.04	0.26
Short-Term Investments	0	2.98	0	0	0
Cash & Cash Equivalents	5.32	11.14	6.9	4.04	0.26
Cash Growth	-52.23%	61.44%	70.98%	1448.00%	885.19%
Receivables	0	0.03	0.05	0	0
Inventory	1.73	0.7	0.1	0	0
Other Current Assets	0.26	0.3	0.24	0.12	0.04
Total Current Assets	7.31	12.18	7.29	4.16	0.3
Property, Plant & Equipment	0.69	0.53	0.51	0.45	0.05
Goodwill and Intangibles	0.09	0.11	0.13	0.16	0.18
Total Long-Term Assets	0.78	0.65	0.65	0.6	0.23
Total Assets	8.1	12.82	7.94	4.76	0.53
Accounts Payable	0.69	0.93	0.53	0.76	1.15
Deferred Revenue	0	1.46	0.01	0.07	0
Current Debt	0	0	0	1.01	0
Other Current Liabilities	1.11	0.72	0.64	0.51	0.62
Total Current Liabilities	1.79	3.1	1.18	2.36	1.77
Long-Term Debt	0.06	0.12	0.2	0.25	0
Other Long-Term Liabilities	0	0	0	0.08	0
Total Long-Term Liabilities	0.06	0.12	0.2	0.34	0
Total Liabilities	1.85	3.22	1.38	2.69	1.77
Total Debt	0.06	0.12	0.2	1.26	0
Debt Growth	-53.76%	-41.07%	-83.92%	-	-
Retained Earnings	-62.69	-50.83	-40.83	-30.88	-17.24
Shareholders' Equity	6.25	9.6	6.55	2.07	-1.24
Net Cash / Debt	5.27	11.02	6.7	2.77	0.26
Net Cash / Debt Growth	-52.21%	64.54%	141.40%	964.19%	-
Net Cash Per Share	0.29	0.69	0.63	0.51	0.07
Working Capital	5.52	9.08	6.11	1.8	-1.47
Book Value Per Share	0.34	0.60	0.61	0.38	-0.31

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).